248 related articles for article (PubMed ID: 24006850)
1. Interrogation of ERG gene rearrangements in prostate cancer identifies a prognostic 10-gene signature with relevant implication to patients' clinical outcome.
Bismar TA; Alshalalfa M; Petersen LF; Teng LH; Gerke T; Bakkar A; Al-Mami A; Liu S; Dolph M; Mucci LA; Alhajj R
BJU Int; 2014 Feb; 113(2):309-19. PubMed ID: 24006850
[TBL] [Abstract][Full Text] [Related]
2. ERG protein expression reflects hormonal treatment response and is associated with Gleason score and prostate cancer specific mortality.
Bismar TA; Dolph M; Teng LH; Liu S; Donnelly B
Eur J Cancer; 2012 Mar; 48(4):538-46. PubMed ID: 22300588
[TBL] [Abstract][Full Text] [Related]
3. PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer.
Bismar TA; Yoshimoto M; Vollmer RT; Duan Q; Firszt M; Corcos J; Squire JA
BJU Int; 2011 Feb; 107(3):477-85. PubMed ID: 20590547
[TBL] [Abstract][Full Text] [Related]
4. Altered DNA methylation landscapes of polycomb-repressed loci are associated with prostate cancer progression and ERG oncogene expression in prostate cancer.
Kron K; Trudel D; Pethe V; Briollais L; Fleshner N; van der Kwast T; Bapat B
Clin Cancer Res; 2013 Jul; 19(13):3450-61. PubMed ID: 23549870
[TBL] [Abstract][Full Text] [Related]
5. ERG protein expression and gene rearrangements are present at lower rates in metastatic and locally advanced castration-resistant prostate cancer compared to localized disease.
Teng LH; Wang C; Bégin LR; Dolph M; Yilmaz A; Trpkov K; Donnelly B; Bismar TA
Urology; 2013 Aug; 82(2):394-9. PubMed ID: 23746715
[TBL] [Abstract][Full Text] [Related]
6. Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes.
Tomlins SA; Alshalalfa M; Davicioni E; Erho N; Yousefi K; Zhao S; Haddad Z; Den RB; Dicker AP; Trock BJ; DeMarzo AM; Ross AE; Schaeffer EM; Klein EA; Magi-Galluzzi C; Karnes RJ; Jenkins RB; Feng FY
Eur Urol; 2015 Oct; 68(4):555-67. PubMed ID: 25964175
[TBL] [Abstract][Full Text] [Related]
7. High alpha-methylacyl-CoA racemase (AMACR) is associated with ERG expression and with adverse clinical outcome in patients with localized prostate cancer.
Box A; Alshalalfa M; Hegazy SA; Donnelly B; Bismar TA
Tumour Biol; 2016 Sep; 37(9):12287-12299. PubMed ID: 27271990
[TBL] [Abstract][Full Text] [Related]
8. βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion.
Tsourlakis MC; Weigand P; Grupp K; Kluth M; Steurer S; Schlomm T; Graefen M; Huland H; Salomon G; Steuber T; Wilczak W; Sirma H; Simon R; Sauter G; Minner S; Quaas A
Am J Pathol; 2014 Mar; 184(3):609-17. PubMed ID: 24378408
[TBL] [Abstract][Full Text] [Related]
9. ERG rearrangement for predicting subsequent cancer diagnosis in high-grade prostatic intraepithelial neoplasia and lymph node metastasis.
Gao X; Li LY; Zhou FJ; Xie KJ; Shao CK; Su ZL; Sun QP; Chen MK; Pang J; Zhou XF; Qiu JG; Wen XQ; Yang M; Bai XZ; Zhang H; Ling L; Chen Z
Clin Cancer Res; 2012 Aug; 18(15):4163-72. PubMed ID: 22696228
[TBL] [Abstract][Full Text] [Related]
10. A 36-gene signature predicts clinical progression in a subgroup of ERG-positive prostate cancers.
Gasi Tandefelt D; Boormans JL; van der Korput HA; Jenster GW; Trapman J
Eur Urol; 2013 Dec; 64(6):941-50. PubMed ID: 23490727
[TBL] [Abstract][Full Text] [Related]
11. Nuclear C-MYC expression level is associated with disease progression and potentially predictive of two year overall survival in prostate cancer.
Zeng W; Sun H; Meng F; Liu Z; Xiong J; Zhou S; Li F; Hu J; Hu Z; Liu Z
Int J Clin Exp Pathol; 2015; 8(2):1878-88. PubMed ID: 25973080
[TBL] [Abstract][Full Text] [Related]
12. The prognostic significance of combined ERG and androgen receptor expression in patients with prostate cancer managed by androgen deprivation therapy.
Huang KC; Alshalalfa M; Hegazy SA; Dolph M; Donnelly B; Bismar TA
Cancer Biol Ther; 2014 Sep; 15(9):1120-8. PubMed ID: 24972028
[TBL] [Abstract][Full Text] [Related]
13. Cysteine- rich secretory protein 3 (CRISP3), ERG and PTEN define a molecular subtype of prostate cancer with implication to patients' prognosis.
Al Bashir S; Alshalalfa M; Hegazy SA; Dolph M; Donnelly B; Bismar TA
J Hematol Oncol; 2014 Mar; 7():21. PubMed ID: 24606912
[TBL] [Abstract][Full Text] [Related]
14. Gene expression signature of Gleason score is associated with prostate cancer outcomes in a radical prostatectomy cohort.
Jhun MA; Geybels MS; Wright JL; Kolb S; April C; Bibikova M; Ostrander EA; Fan JB; Feng Z; Stanford JL
Oncotarget; 2017 Jun; 8(26):43035-43047. PubMed ID: 28496006
[TBL] [Abstract][Full Text] [Related]
15. Expression of cell cycle-regulated genes and prostate cancer prognosis in a population-based cohort.
Rubicz R; Zhao S; April C; Wright JL; Kolb S; Coleman I; Lin DW; Nelson PS; Ostrander EA; Feng Z; Fan JB; Stanford JL
Prostate; 2015 Sep; 75(13):1354-62. PubMed ID: 25990700
[TBL] [Abstract][Full Text] [Related]
16. The expression profile and heterogeneity analysis of ERG in 633 consecutive prostate cancers from a single center.
Nie L; Pan X; Zhang M; Yin X; Gong J; Chen X; Xu M; Zhou Q; Chen N
Prostate; 2019 Jun; 79(8):819-825. PubMed ID: 30900303
[TBL] [Abstract][Full Text] [Related]
17. ERG Expression in Prostate Needle Biopsy: Potential Diagnostic and Prognostic Implications.
Lee SL; Yu D; Wang C; Saba R; Liu S; Trpkov K; Donnelly B; Bismar TA
Appl Immunohistochem Mol Morphol; 2015 Aug; 23(7):499-505. PubMed ID: 25517865
[TBL] [Abstract][Full Text] [Related]
18. Relative 8q gain predicts disease-specific survival irrespective of the TMPRSS2-ERG fusion status in diagnostic biopsies of prostate cancer.
Barros-Silva JD; Ribeiro FR; Rodrigues A; Cruz R; Martins AT; Jerónimo C; Henrique R; Teixeira MR
Genes Chromosomes Cancer; 2011 Aug; 50(8):662-71. PubMed ID: 21584900
[TBL] [Abstract][Full Text] [Related]
19. Clinical value of ERG, TFF3, and SPINK1 for molecular subtyping of prostate cancer.
Terry S; Nicolaiew N; Basset V; Semprez F; Soyeux P; Maillé P; Vacherot F; Ploussard G; Londoño-Vallejo A; de la Taille A; Allory Y
Cancer; 2015 May; 121(9):1422-30. PubMed ID: 25639219
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic signature of Gleason score and prostate cancer recurrence after radical prostatectomy.
Geybels MS; Wright JL; Bibikova M; Klotzle B; Fan JB; Zhao S; Feng Z; Ostrander EA; Lin DW; Nelson PS; Stanford JL
Clin Epigenetics; 2016; 8():97. PubMed ID: 27651837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
